Shares of Pfizer Inc. (NYSE:PFE) have received a consensus recommendation of “Hold” from the twenty-three research firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $39.47.
PFE has been the topic of a number of recent research reports. BMO Capital Markets set a $37.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, October 10th. Barclays set a $38.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Deutsche Bank set a $38.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Monday, October 16th.
Pfizer (NYSE:PFE) traded up $0.08 during mid-day trading on Friday, reaching $35.36. The company’s stock had a trading volume of 5,884,517 shares, compared to its average volume of 24,105,199. Pfizer has a 52 week low of $31.67 and a 52 week high of $39.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market capitalization of $210,290.00, a P/E ratio of 10.05, a price-to-earnings-growth ratio of 2.08 and a beta of 0.94.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter in the prior year, the company earned $0.47 earnings per share. Pfizer’s revenue was up .6% on a year-over-year basis. sell-side analysts anticipate that Pfizer will post 2.94 EPS for the current year.
Pfizer declared that its board has approved a stock repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.85%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is 38.64%.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares in the company, valued at $3,827,946. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. HL Financial Services LLC grew its holdings in Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after buying an additional 35,744 shares in the last quarter. Hartford Financial Management Inc. grew its holdings in Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 835 shares in the last quarter. Cadence Bank NA grew its holdings in Pfizer by 1.4% during the 2nd quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 1,428 shares in the last quarter. Majedie Asset Management Ltd grew its holdings in Pfizer by 7.9% during the 2nd quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after buying an additional 24,531 shares in the last quarter. Finally, Stanley Laman Group Ltd. grew its holdings in Pfizer by 373.7% during the 2nd quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after buying an additional 90,160 shares in the last quarter. Hedge funds and other institutional investors own 69.87% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set Pfizer Inc. (PFE) PT at $39.26” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/14/brokerages-set-pfizer-inc-pfe-pt-at-39-26.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.